Synergy Pharmaceuticals — Technical Presentation (June 2009)
20 slides from Synergy Pharmaceuticals's technical presentation, Jun 3, 2009
Slide 1: Randomized, Double-blind, Placebo-Controlled, Single Ascending Oral-Dose Study of SP-304
A Randomized, Double-blind, Placebo-Controlled, Single-, Ascending-, Oral-Dose Safety, Tolerability and Pharmacokinetic Study of SP-304 in Healthy Adult Human Male and Female Volunteers Kunwar Shailubhai, Ph.D. William Gerson, D.O. Craig Talluto, Ph.D. Gary Jacob, Ph.D.
Slide 2: SP-304 Uroguanylin Analog
SP-304 SP-304 Uroguanylin Analog Uroguanylin Natural Hormone NDECELCVNVACTGCL GC-C Receptor Single letters denote different amino acids. Colored lines denote disulphide bonds 16-mer analog of uroguanylin Single key amino acid change Locked into stable active conformer Compact stable molecule Thermo
Slide 3: Physiological Mechanism of GC-C Agonists
Physiological Mechanism of GC-C Agonists Guanylate Cyclase C (GC-C) receptors are present on luminal side of gut Orally administered SP-304 activates GC-C receptor, which leads to activation of CFTR The CFTR when activated secretes Cl- and HCO3- into intestinal lumen, along with water Enhance secret
Slide 4: Activation of chloride channels increases fluid secretion into the GI lumen
Activation of chloride channels increases fluid secretion into the GI lumen Amitiza® SP-304
Slide 5: Purpose
Purpose The purpose of this was to characterize the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) effects of SP-304 in healthy volunteers
Slide 6: Inclusion Criteria
Inclusion Criteria Healthy male or female, between 18 and 64 years of age with a body mass index (BMI) between 18 and 29 kg/m2 Negative test for drugs of abuse, hepatitis B and C and HIV Abstain from caffeinated beverages, alcohol and nicotine for a period of 36 hours pre-dose through 48-hours post-
Slide 7: Exclusion Criteria
Exclusion Criteria Any pre-existing medical condition considered clinically significant by the Principal Investigator (PI) Clinically significant abnormal laboratory results at Screening Participation in a clinical trial using an investigational drug within 30 days of the Screening visit Ingested, i
Slide 8: Exclusion Criteria
Exclusion Criteria Received any treatment agents, herbs, or foods (e.g., grapefruit juice) known to inhibit or induce enzymes within the cytochrome P450 system, within 7 days prior to Day 1 dosing Taken any class of phosphodiesterase inhibitors within 3 days prior to Day 1 dosing Any episode of abno
Slide 9: Exclusion Criteria
Exclusion Criteria Failure to complete the Screening bowel movement diary accurately and completely for 7 consecutive days (during the 14 day Screening period) prior to Day 1 dosing Donation of blood (> 1 pint) within 8 weeks, donation of plasma within 2 weeks prior to the Screening visit, or receip
Slide 10: Methods
Methods Subjects completed a 7-day bowel movement diary during the 14-day screening period 7 consecutive days Bristol Stool From Scale (BSFS) used to asses consistency of bowel movements Subjects checked into the Phase 1 unit 1 day prior to dosing Pre-dose lab tests were performed to confirm eligibi
Slide 11: Methods
Methods Randomized 6:2 (active:placebo) Subjects were dosed at 9:00am (fasting) PK blood draws were taken pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose All post-dose bowel movements were reported to Phase I unit staff Consistency of the stool was graded by the Phase I un
Slide 12: Treatment Groups
Treatment Groups Cohort 1: SP-304 0.1 mg once or matching placebo Cohort 2: SP-304 0.3 mg once or matching placebo Cohort 3: SP-304 0.9 mg once or matching placebo Cohort 4: SP-304 2.7 mg once or matching placebo Cohort 5: SP-304 5.4 mg once or matching placebo Cohort 6: SP-304 8.1 mg once or matchi
Slide 13: Subject Characteristics
Subject Characteristics
Slide 14: Bristol Score of First Bowel Movement Following a Single Dose of SP-304
Bristol Score of First Bowel Movement Following a Single Dose of SP-304 2.0 3.0 4.0 5.0 6.0 -1 0 1 2 3 4 5 6 7 8 Dose (mg) Bristol Score
Slide 15: Average time to first bowel movement post-dose
Average time to first bowel movement through 24 hr post-dose 0:00 2:24 4:48 7:12 9:36 12:00 14:24 16:48 19:12 21:36 Placebo 0.1 0.3 0.9 2.7 5.4 8.1 16.2 24.3 48.6 Average Time ± SEM SP-304 (mg) SP-304 Single-dose data in volunteers
Slide 16: SP-304 improves stool consistency
SP-304 improves stool consistency SP-304 Single-Dose Data 0 20 40 60 80 Placebo 0.1 0.3 0.9 2.7 5.4 8.1 16.2 24.3 48.6 % Number of Subjects n=16 n=6 n=6 n=6 n=6 n=6 n=6 n=5 n=6 n=6 Note: Bristol scores for normal and healthy subjects are between 3 and 4
Slide 17: SP-304 improves stool consistency
SP-304 improves stool consistency * Wilcoxon Two-sample test treatment vs placebo one-sided Placebo 0.1 0.3 0.9 2.7 5.4 8.1 16.2 24.3 48.6 Single Dose (mg) Bristol Score of first BM 0 1 2 3 4 5 6 7 p < 0.05 p < 0.05 p < 0.01 p < 0.01 SP-304 Single-Dose Data
Slide 18: Adverse Event (AE) Profile
Adverse Event (AE) Profile Common Terminology Criteria for Adverse Events (CTCAE), version 3.0, was used to assess all adverse events 12 out of 63 subjects (19%) reported mild AEs All AEs resolved within 2 hours of dosing All AEs resolved within 24 hours of being reported Per CTCAE criteria, diarrhe
Slide 19: Adverse Event (AE) Profile
Adverse Event (AE) Profile Number of AEs Reported with an Assigned Relationship to SP-304 * Diarrhea is defined as an increase in the number of bowel movements per day compared to baseline * Adverse Event Term Number Reported % Diarrhea 8 12.70% Abdominal Discomfort 3 4.76% Nausea 2 3.17% Emesis 1 1
Slide 20: Conclusions
Conclusions SP-304 was safe and well-tolerated across all doses No SAEs No severe diarrhea even at very high doses No systemic absorption of orally administered SP-304 SP-304 decreased the time to first bowel movement and increased the Bristol (BSFS) score
Synergy Pharmaceuticals — Technical Presentation (June 2009) on 6ix